|
1
|
Italian Association Medical Oncology
association tumor register. The numbers of cancer in Italy. 2017,
simplehttp://www.registri-tumori.it/cms/pubblicazioni/i-numeri-del-cancro-italia-2017Published
September, 2017. July 6–2018
|
|
2
|
Huguet JM, Lobo M, Labrador JM, Boix C,
Albert C, Ferrer-Barceló L, Durá AB, Suárez P, Iranzo I, Gil-Raga
M, et al: Diagnostic-therapeutic management of bile duct cancer.
World J Clin Cases. 7:1732–1752. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Glimelius B, Hoffman K, Sjödén PO,
Jacobsson G, Sellström H, Enander LK, Linné T and Svensson C:
Chemotherapy improves survival and quality of life in advanced
pancreatic and biliary cancer. Ann Oncol. 7:593–600. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Valle J, Wasan H, Palmer DH, Cunningham D,
Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira
SP, et al ABC-02 Trial Investigators, : Cisplatin plus gemcitabine
versus gemcitabine for biliary tract cancer. N Engl J Med.
362:1273–1281. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jain A and Javle M: Molecular profiling of
biliary tract cancer: A target rich disease. J Gastrointest Oncol.
7:797–803. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jusakul A, Cutcutache I, Yong CH, Lim JQ,
Huang MN, Padmanabhan N, Nellore V, Kongpetch S, Ng AWT, Ng LM, et
al: Whole-Genome and Epigenomic Landscapes of Etiologically
Distinct Subtypes of Cholangiocarcinoma. Cancer Discov.
7:1116–1135. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Javle M, Lowery M, Shroff RT, Weiss KH,
Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S,
Macarulla T, et al: Phase II Study of BGJ398 in Patients With
FGFR-Altered Advanced Cholangiocarcinoma. J Clin Oncol. 36:276–282.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Goyal L, Arkenau HT, Tran B, Soria J-C,
Bahleda R, Mak G, Zhu A, Javle M, Hiroshi H, Benedetti F, et al:
Early clinical efficacy of TAS-120, a covalently bound FGFR
inhibitor, in patients with cholangiocarcinoma. Ann Oncol. 28
(Suppl 3):202017. View Article : Google Scholar
|
|
9
|
Blair AB and Murphy A: Immunotherapy as a
treatment for biliary tract cancers: A review of approaches with an
eye to the future. Curr Probl Cancer. 42:49–58. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Davies KD and Doebele RC: Molecular
pathways: ROS1 fusion proteins in cancer. Clin Cancer Res.
19:4040–4045. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Uguen A and De Braekeleer M: ROS1 fusions
in cancer: A review. Future Oncol. 12:1911–1928. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bansal M, He J, Peyton M, Kustagi M, Iyer
A, Comb M, White M, Minna JD and Califano A: Elucidating
synergistic dependencies in lung adenocarcinoma by proteome-wide
signaling-network analysis. PLoS One. 14:e02086462019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bergethon K, Shaw AT, Ou SH, Katayama R,
Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang
R, et al: ROS1 rearrangements define a unique molecular class of
lung cancers. J Clin Oncol. 30:863–870. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jänne PA and Meyerson M; J2012 PA, : ROS1
rearrangements in lung cancer: A new genomic subset of lung
adenocarcinoma. J Clin Oncol. 30:878–879. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shaw AT, Ou SH, Bang YJ, Camidge DR,
Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa
DB, et al: Crizotinib in ROS1-rearranged non-small-cell lung
cancer. N Engl J Med. 371:1963–1971. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mazières J, Zalcman G, Crinò L, Biondani
P, Barlesi F, Filleron T, Dingemans AM, Léna H, Monnet I,
Rothschild SI, et al: Crizotinib therapy for advanced lung
adenocarcinoma and a ROS1 rearrangement: results from the EUROS1
cohort. J Clin Oncol. 33:992–999. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chiari R, Buttitta F, Iacono D, Bennati C,
Metro G, Di Lorito A, Iezzi M, Tiseo M, Mazzoni F, Cappuzzo F, et
al: Dramatic response to crizotinib in ROS1 fluorescent in situ
hybridization- and immunohistochemistry-positive lung
adenocarcinoma: a case series. Clin Lung Cancer. 15:470–474. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Landi L, Chiari R, Tiseo M, D'Incà F,
Dazzi C, Chella A, Delmonte A, Bonanno L, Giannarelli D, Cortinovis
DL, et al: Crizotinib in MET-Deregulated or ROS1-Rearranged
Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II,
Prospective, Multicenter, Two-Arms Trial. Clin Cancer Res.
25:7312–7319. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Petreni P, Mazzoni F, Meoni G, Lunghi A,
Cecere FL, Muto A and Di Costanzo F: Outcome of crizotinib
treatment in a young woman with heavily pretreated ROS1-positive
lung cancer. Tumori. 101:e103–e106. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gu TL, Deng X, Huang F, Tucker M, Crosby
K, Rimkunas V, Wang Y, Deng G, Zhu L, Tan Z, et al: Survey of
tyrosine kinase signaling reveals ROS kinase fusions in human
cholangiocarcinoma. PLoS One. 6:e156402011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu P, Wu Y, Sun L, Zuo Q and Shi M: ROS
kinase fusions are not common in Chinese patients with
cholangiocarcinoma. Nan Fang Yi Ke Da Xue Xue Bao. 33:474–478.
2013.PubMed/NCBI
|
|
22
|
Graham RP, Barr Fritcher EG, Pestova E,
Schulz J, Sitailo LA, Vasmatzis G, Murphy SJ, McWilliams RR, Hart
SN, Halling KC, et al: Fibroblast growth factor receptor 2
translocations in intrahepatic cholangiocarcinoma. Hum Pathol.
45:1630–1638. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kipp BR, Voss JS, Kerr SE, Barr Fritcher
EG, Graham RP, Zhang L, Highsmith WE, Zhang J, Roberts LR, Gores
GJ, et al: Isocitrate dehydrogenase 1 and 2 mutations in
cholangiocarcinoma. Hum Pathol. 43:1552–1558. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee KH, Lee KB, Kim TY, Han SW, Oh DY, Im
SA, Kim TY, Yi NJ, Lee KW, Suh KS, et al: Clinical and pathological
significance of ROS1 expression in intrahepatic cholangiocarcinoma.
BMC Cancer. 15:7212015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lim SM, Yoo JE, Lim KH, Meng Tai DW, Cho
BC and Park YN: Rare Incidence of ROS1 Rearrangement in
Cholangiocarcinoma. Cancer Res Treat. 49:185–192. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rossi G, Jocollé G, Conti A, Tiseo M, Zito
Marino F, Donati G, Franco R, Bono F, Barbisan F and Facchinetti F:
Detection of ROS1 rearrangement in non-small cell lung cancer:
Current and future perspectives. Lung Cancer (Auckl). 8:45–55.
2017.PubMed/NCBI
|
|
27
|
Conde E, Hernandez S, Martinez R, De
Castro J, Collazo-Lorduy A, Jimenez B, Muriel A, Mate JL, Morán T,
Aranda I, et al: Evaluation of a Novel ROS1 Immunohistochemistry
Clone (SP384) for the Identification of ROS1 Rearrangements in
NSCLC Patients. J Thorac Oncol. 13 (Suppl 10):S553–S554. 2018.
View Article : Google Scholar
|
|
28
|
Arai Y, Totoki Y, Hosoda F, Shirota T,
Hama N, Nakamura H, Ojima H, Furuta K, Shimada K, Okusaka T, et al:
Fibroblast growth factor receptor 2 tyrosine kinase fusions define
a unique molecular subtype of cholangiocarcinoma. Hepatology.
59:1427–1434. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bubendorf L, Büttner R, Al-Dayel F, Dietel
M, Elmberger G, Kerr K, López-Ríos F, Marchetti A, Öz B, Pauwels P,
et al: Testing for ROS1 in non-small cell lung cancer: A review
with recommendations. Virchows Arch. 469:489–503. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Abou-Alfa GK, Andersen JB, Chapman W,
Choti M, Forbes SJ, Gores GJ, Hong TS, Harding JJ, Vander Heiden
MG, Javle M, et al: Advances in cholangiocarcinoma research: Report
from the third Cholangiocarcinoma Foundation Annual Conference. J
Gastrointest Oncol. 7:819–827. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lowery MA, Ptashkin R, Jordan E, Berger
MF, Zehir A, Capanu M, Kemeny NE, O'Reilly EM, El-Dika I, Jarnagin
WR, et al: Comprehensive Molecular Profiling of Intrahepatic and
Extrahepatic Cholangiocarcinomas: Potential Targets for
Intervention. Clin Cancer Res. 24:4154–4161. 2018. View Article : Google Scholar : PubMed/NCBI
|
